{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T14:06:16Z","timestamp":1767708376288,"version":"3.48.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-30172-5","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T09:28:02Z","timestamp":1765186082000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between lifetime co-use of classic psychedelics and cannabis and prostate cancer diagnosis among US adults 50 years and older"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0961-9665","authenticated-orcid":false,"given":"Amrit","family":"Baral","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WayWay M.","family":"Hlaing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Garcia-Romeu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo S.","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise C.","family":"Vidot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"30172_CR1","unstructured":"Key Statistics for Prostate Cancer. Accessed 3 February 2025; https:\/\/www.cancer.org\/cancer\/types\/prostate-cancer\/about\/key-statistics.html (2025)."},{"key":"30172_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.811044","volume":"10","author":"L Wang","year":"2022","unstructured":"Wang, L. et al. Prostate cancer incidence and mortality: Global status and temporal trends in 89 countries from 2000 to 2019. Front. Public Health 10, 811044 (2022).","journal-title":"Front. Public Health"},{"issue":"10437","key":"30172_CR3","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","volume":"403","author":"ND James","year":"2024","unstructured":"James, N. D. et al. The lancet commission on prostate cancer: Planning for the surge in cases. Lancet 403(10437), 1683\u20131722 (2024).","journal-title":"Lancet"},{"issue":"2","key":"30172_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla, P. Epidemiology of prostate cancer. World J. Oncol. 10(2), 63 (2019).","journal-title":"World J. Oncol."},{"issue":"1","key":"30172_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","volume":"77","author":"MB Culp","year":"2020","unstructured":"Culp, M. B., Soerjomataram, I., Efstathiou, J. A., Bray, F. & Jemal, A. Recent global patterns in prostate cancer incidence and mortality rates. Eur. Urol. 77(1), 38\u201352 (2020).","journal-title":"Eur. Urol."},{"key":"30172_CR6","unstructured":"Centers for Disease Control and Prevention. U.S. Cancer Statistics: Prostate Cancer Incidence by Stage at Diagnosis. U.S. Department of Health and Human Services, CDC, accessed 14 August 2025; https:\/\/www.cdc.gov\/united-states-cancer-statistics\/publications\/prostate-cancer.html (2024)."},{"key":"30172_CR7","unstructured":"National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: Prostate Cancer. SEER; accessed 14 August 2025; https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html."},{"issue":"16","key":"30172_CR8","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1002\/cncr.34793","volume":"129","author":"AE Sedani","year":"2023","unstructured":"Sedani, A. E., Campbell, J. E. & Beebe, L. A. Cannabis use among cancer survivors in 22 states: Results from the behavioral risk factor surveillance system, 2020. Cancer 129(16), 2499\u20132513 (2023).","journal-title":"Cancer"},{"key":"30172_CR9","doi-asserted-by":"crossref","unstructured":"White, J. D. Complementary and alternative medicine research: A National Cancer Institute perspective. 2002.","DOI":"10.1053\/sonc.2002.50003"},{"issue":"3","key":"30172_CR10","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1177\/1534735411423920","volume":"11","author":"M Horneber","year":"2012","unstructured":"Horneber, M. et al. How many cancer patients use complementary and alternative medicine: A systematic review and metaanalysis. Integr. Cancer Ther. 11(3), 187\u2013203 (2012).","journal-title":"Integr. Cancer Ther."},{"issue":"3","key":"30172_CR11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1017\/S1478951503030256","volume":"1","author":"Z Nahleh","year":"2003","unstructured":"Nahleh, Z. & Tabbara, I. A. Complementary and alternative medicine in breast cancer patients. Palliat. Support. Care 1(3), 267\u2013273 (2003).","journal-title":"Palliat. Support. Care"},{"issue":"9","key":"30172_CR12","first-page":"7491","volume":"30","author":"NJ Raghunathan","year":"2022","unstructured":"Raghunathan, N. J. et al. In the weeds: A retrospective study of patient interest in and experience with cannabis at a cancer center. Support. Care Cancer 30(9), 7491\u20137497 (2022).","journal-title":"Support. Care Cancer"},{"issue":"4","key":"30172_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/09540261.2018.1482261","volume":"30","author":"S Ross","year":"2018","unstructured":"Ross, S. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. Int. Rev. Psychiatry 30(4), 317\u2013330 (2018).","journal-title":"Int. Rev. Psychiatry"},{"issue":"37","key":"30172_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/jncimonographs\/lgm005","volume":"2007","author":"CS Cleeland","year":"2007","unstructured":"Cleeland, C. S. Symptom burden: Multiple symptoms and their impact as patient-reported outcomes. J. Natl. Cancer Inst. Monogr. 2007(37), 16\u201321 (2007).","journal-title":"J. Natl. Cancer Inst. Monogr."},{"issue":"58","key":"30172_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/jncimonographs\/lgab011","volume":"2021","author":"M Sexton","year":"2021","unstructured":"Sexton, M., Garcia, J. M., Jatoi, A., Clark, C. S. & Wallace, M. S. The management of cancer symptoms and treatment-induced side effects with cannabis or cannabinoids. JNCI Monogr. 2021(58), 86\u201398 (2021).","journal-title":"JNCI Monogr."},{"issue":"66","key":"30172_CR16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1093\/jncimonographs\/lgad037","volume":"2024","author":"DC Vidot","year":"2024","unstructured":"Vidot, D. C. et al. Ethnic differences in the patterns, sources, and reasons for cannabis use among cancer patients at an NCI-Designated Cancer Center. JNCI Monogr. 2024(66), 252\u2013258 (2024).","journal-title":"JNCI Monogr."},{"issue":"21","key":"30172_CR17","doi-asserted-by":"publisher","first-page":"e70384","DOI":"10.1002\/cam4.70384","volume":"13","author":"A Baral","year":"2024","unstructured":"Baral, A. et al. Cannabis use among cancer patients during active treatment: Findings from a study at an NCI-designated cancer center. Cancer Med. 13(21), e70384 (2024).","journal-title":"Cancer Med."},{"key":"30172_CR18","unstructured":"Baral, A. et al. State of the science: Health care provider communication of cannabis use among adults living with cancer. J. Cancer Educ. 1\u201319 (2024)."},{"key":"30172_CR19","doi-asserted-by":"crossref","unstructured":"Smith LA, Azariah F, Lavender VTC, Stoner NS, Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst. Rev. 2015(11).","DOI":"10.1002\/14651858.CD009464.pub2"},{"issue":"7303","key":"30172_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/bmj.323.7303.16","volume":"323","author":"MR Tram\u00e8r","year":"2001","unstructured":"Tram\u00e8r, M. R. et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323(7303), 16 (2001).","journal-title":"BMJ"},{"issue":"Suppl 2","key":"30172_CR21","first-page":"S215","volume":"6","author":"A Blake","year":"2018","unstructured":"Blake, A. et al. A selective review of medical cannabis in cancer pain management. Ann. Palliat. Med. 6(Suppl 2), S215\u2013S222 (2018).","journal-title":"Ann. Palliat. Med."},{"issue":"1","key":"30172_CR22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12888-022-03948-6","volume":"22","author":"N Kuhathasan","year":"2022","unstructured":"Kuhathasan, N., Minuzzi, L., MacKillop, J. & Frey, B. N. An investigation of cannabis use for insomnia in depression and anxiety in a naturalistic sample. BMC Psychiatry 22(1), 303 (2022).","journal-title":"BMC Psychiatry"},{"issue":"04","key":"30172_CR23","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1055\/a-1341-1907","volume":"54","author":"LJ Mertens","year":"2021","unstructured":"Mertens, L. J. & Preller, K. H. Classical psychedelics as therapeutics in psychiatry\u2013current clinical evidence and potential therapeutic mechanisms in substance use and mood disorders. Pharmacopsychiatry 54(04), 176\u2013190 (2021).","journal-title":"Pharmacopsychiatry"},{"key":"30172_CR24","doi-asserted-by":"crossref","unstructured":"Nichols, C. D. & Hendricks, P. S. Classic psychedelics as therapeutics for psychiatric disorders. In Handbook of Behavioral Neuroscience Vol. 31 959\u2013966 (Elsevier, 2020).","DOI":"10.1016\/B978-0-444-64125-0.00049-9"},{"key":"30172_CR25","doi-asserted-by":"crossref","unstructured":"Chi, T. & Gold, J. A. A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses. J. Neurol. Sci. 411 (2020).","DOI":"10.1016\/j.jns.2020.116715"},{"key":"30172_CR26","doi-asserted-by":"publisher","DOI":"10.1017\/S147895152500032X","volume":"23","author":"MI Lapid","year":"2025","unstructured":"Lapid, M. I. et al. Evaluating the effectiveness of psilocybin in alleviating distress among cancer patients: A systematic review. Palliat. Support. Care 23, e99 (2025).","journal-title":"Palliat. Support. Care"},{"issue":"6","key":"30172_CR27","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/cncr.35010","volume":"129","author":"M Agrawal","year":"2023","unstructured":"Agrawal, M. et al. Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder. Cancer 129(6), 991\u2013998. https:\/\/doi.org\/10.1002\/cncr.35010 (2023).","journal-title":"Cancer"},{"issue":"1","key":"30172_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1556\/2054.2022.00222","volume":"4","author":"BR Lewis","year":"2023","unstructured":"Lewis, B. R. et al. Group format psychedelic-assisted therapy interventions: Observations and impressions from the HOPE trial. J. Psychedelic Stud. 4(1), 123\u2013134. https:\/\/doi.org\/10.1556\/2054.2022.00222 (2023).","journal-title":"J. Psychedelic Stud."},{"key":"30172_CR29","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jad.2022.11.046","volume":"323","author":"S Shnayder","year":"2023","unstructured":"Shnayder, S. et al. Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients. J. Affect. Disord. 323, 592\u2013597. https:\/\/doi.org\/10.1016\/j.jad.2022.11.046 (2023).","journal-title":"J. Affect. Disord."},{"key":"30172_CR30","first-page":"1090","volume":"4","author":"D Roberto","year":"2017","unstructured":"Roberto, D., Klotz, L. H. & Venkateswaran, V. Cannabinoids as an anticancer agent for prostate cancer. J. Urol. Res. 4, 1090\u20131097 (2017).","journal-title":"J. Urol. Res."},{"issue":"08","key":"30172_CR31","doi-asserted-by":"publisher","first-page":"806","DOI":"10.4236\/pp.2014.58091","volume":"5","author":"M Sharma","year":"2014","unstructured":"Sharma, M., Hudson, J. B., Adomat, H., Guns, E. & Cox, M. E. In vitro anticancer activity of plant-derived cannabidiol on prostate cancer cell lines. Pharmacol. Pharm. 5(08), 806 (2014).","journal-title":"Pharmacol. Pharm."},{"issue":"1","key":"30172_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/0970-1591.94942","volume":"28","author":"JA Ramos","year":"2012","unstructured":"Ramos, J. A. & Bianco, F. J. The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications. Indian J. Urol. 28(1), 9\u201314 (2012).","journal-title":"Indian J. Urol."},{"key":"30172_CR33","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3389\/fimmu.2015.00358","volume":"6","author":"A Szabo","year":"2015","unstructured":"Szabo, A. Psychedelics and immunomodulation: Novel approaches and therapeutic opportunities. Front. Immunol. 6, 358 (2015).","journal-title":"Front. Immunol."},{"key":"30172_CR34","doi-asserted-by":"crossref","unstructured":"Flanagan, T. W. & Nichols, C. D. Psychedelics and anti-inflammatory activity in animal models. Disruptive Psychopharmacol. 229\u2013245 (2022).","DOI":"10.1007\/7854_2022_367"},{"issue":"1","key":"30172_CR35","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2174\/1566524015666150114113411","volume":"15","author":"D Sarrouilhe","year":"2015","unstructured":"Sarrouilhe, D., Clarhaut, J., Defamie, N. & Mesnil, M. Serotonin and cancer: What is the link?. Curr. Mol. Med. 15(1), 62\u201377 (2015).","journal-title":"Curr. Mol. Med."},{"key":"30172_CR36","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.biochi.2018.06.016","volume":"161","author":"D Sarrouilhe","year":"2019","unstructured":"Sarrouilhe, D. & Mesnil, M. Serotonin and human cancer: A critical view. Biochimie 161, 46\u201350 (2019).","journal-title":"Biochimie"},{"key":"30172_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15436\/2377-0902.17.1629","volume":"5","author":"S Zaminpira","year":"2018","unstructured":"Zaminpira, S. & Niknamian, S. The impact of the serotonin on the cause and treatment of cancer. Int. J. Cancer Oncol. 5, 1\u20137 (2018).","journal-title":"Int. J. Cancer Oncol."},{"issue":"4","key":"30172_CR38","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1002\/hep.23441","volume":"51","author":"C Soll","year":"2010","unstructured":"Soll, C. et al. Serotonin promotes tumor growth in human hepatocellular cancer. Hepatology 51(4), 1244\u20131254 (2010).","journal-title":"Hepatology"},{"issue":"13","key":"30172_CR39","doi-asserted-by":"publisher","first-page":"5152","DOI":"10.1158\/0008-5472.CAN-08-0202","volume":"68","author":"A Nocito","year":"2008","unstructured":"Nocito, A. et al. Serotonin regulates macrophage-mediated angiogenesis in a mouse model of colon cancer allografts. Can. Res. 68(13), 5152\u20135158 (2008).","journal-title":"Can. Res."},{"issue":"4","key":"30172_CR40","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1001\/jama.1971.03190040067022","volume":"217","author":"LJ Levick","year":"1971","unstructured":"Levick, L. J. & Levick, S. N. Testicular choriocarcinoma in LSD users: Coincidence or cause?. JAMA 217(4), 475\u2013476 (1971).","journal-title":"JAMA"},{"issue":"25","key":"30172_CR41","doi-asserted-by":"publisher","first-page":"6508","DOI":"10.1523\/JNEUROSCI.0678-08.2008","volume":"28","author":"AR Best","year":"2008","unstructured":"Best, A. R. & Regehr, W. G. Serotonin evokes endocannabinoid release and retrogradely suppresses excitatory synapses. J. Neurosci. 28(25), 6508\u20136515 (2008).","journal-title":"J. Neurosci."},{"issue":"1","key":"30172_CR42","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1152\/jn.91054.2008","volume":"101","author":"WM Connelly","year":"2009","unstructured":"Connelly, W. M. & Baggott, M. J. Role of endocannabinoids in 5-HT2 receptor-mediated effects. J. Neurophysiol. 101(1), 5\u20137 (2009).","journal-title":"J. Neurophysiol."},{"issue":"1","key":"30172_CR43","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/glia.24280","volume":"71","author":"CE Martinez Ramirez","year":"2023","unstructured":"Martinez Ramirez, C. E. et al. Endocannabinoid signaling in the central nervous system. Glia 71(1), 5\u201335 (2023).","journal-title":"Glia"},{"issue":"3","key":"30172_CR44","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.neuropharm.2011.02.016","volume":"61","author":"S Haj-Dahmane","year":"2011","unstructured":"Haj-Dahmane, S. & Shen, R.-Y. Modulation of the serotonin system by endocannabinoid signaling. Neuropharmacology 61(3), 414\u2013420 (2011).","journal-title":"Neuropharmacology"},{"issue":"5","key":"30172_CR45","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.genm.2010.09.004","volume":"7","author":"JH Cotto","year":"2010","unstructured":"Cotto, J. H. et al. Gender effects on drug use, abuse, and dependence: A special analysis of results from the National Survey on Drug Use and Health. Gend. Med. 7(5), 402\u2013413 (2010).","journal-title":"Gend. Med."},{"key":"30172_CR46","doi-asserted-by":"crossref","unstructured":"Oppegaard, K. Gender Differences in the Use of Engagement and Disengagement Coping Strategies (2020).","DOI":"10.1188\/20.ONF.586-594"},{"key":"30172_CR47","doi-asserted-by":"crossref","unstructured":"Dahlman, D., Li, X., Crump, C., Sundquist, J. & Sundquist, K. Drug use disorder and risk of incident and fatal prostate cancer among Swedish men: A nationwide epidemiological study. Cancer Causes Control 1\u201310 (2022).","DOI":"10.1007\/s10552-021-01513-2"},{"issue":"12","key":"30172_CR48","doi-asserted-by":"publisher","first-page":"a030361","DOI":"10.1101\/cshperspect.a030361","volume":"8","author":"CH Pernar","year":"2018","unstructured":"Pernar, C. H., Ebot, E. M., Wilson, K. M. & Mucci, L. A. The epidemiology of prostate cancer. Cold Spring Harb. Perspect. Med. 8(12), a030361 (2018).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"30172_CR49","unstructured":"NSDUH Data Files. Accessed 20 November 2024; https:\/\/www.samhsa.gov\/data\/data-we-collect\/nsduh\/datafiles."},{"key":"30172_CR50","unstructured":"2019 National Survey on Drug Use and Health (NSDUH) Methodological Resource Book Section 13: Statistical Inference Report 2021, accessed 29 October 2024; https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt34666\/NSDUHmrbStatInference2019.pdf."},{"key":"30172_CR51","unstructured":"Center for Behavioral Health Statistics and Quality. 2019 National Survey on Drug Use and Health Public Use File Codebook. Substance Abuse and Mental Health Services Administration; accessed 14 August 2025. https:\/\/www.samhsa.gov\/data\/system\/files\/media-puf-file\/NSDUH-2019-DS0001-info-codebook.pdf (2020)."},{"issue":"5","key":"30172_CR52","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.3390\/biomedicines12051008","volume":"12","author":"T Mohammed","year":"2024","unstructured":"Mohammed, T. et al. Marijuana use may be associated with reduced prevalence of prostate cancer: A national survey on drug use and health study from United States of America. Biomedicines 12(5), 1008 (2024).","journal-title":"Biomedicines"},{"key":"30172_CR53","doi-asserted-by":"crossref","unstructured":"Barnett, B. S., Ziegler, K., Doblin, R. & Carlo, A. D. Is psychedelic use associated with cancer?: Interrogating a half-century-old claim using contemporary population-level data. J. Psychopharmacol. (2022).","DOI":"10.1177\/02698811221117536"},{"issue":"6","key":"30172_CR54","doi-asserted-by":"publisher","first-page":"558","DOI":"10.4097\/kja.19087","volume":"72","author":"JH Kim","year":"2019","unstructured":"Kim, J. H. Multicollinearity and misleading statistical results. Korean J. Anesthesiol. 72(6), 558\u2013569 (2019).","journal-title":"Korean J. Anesthesiol."},{"key":"30172_CR55","unstructured":"Substance Abuse and Mental Health Services Administration. 2015 national survey on drug use and health public use file codebook. Accessed July 2022; https:\/\/www.datafiles.samhsa.gov\/sites\/default\/files\/field-uploads-protected\/studies\/NSDUH-2015\/NSDUH-2015-datasets\/NSDUH-2015-DS0001\/NSDUH-2015-DS0001-info\/NSDUH-2015-DS0001-info-codebook.pdf."},{"issue":"10","key":"30172_CR56","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1177\/02698811221117536","volume":"36","author":"BS Barnett","year":"2022","unstructured":"Barnett, B. S., Ziegler, K., Doblin, R. & Carlo, A. D. Is psychedelic use associated with cancer?: Interrogating a half-century-old claim using contemporary population-level data. J. Psychopharmacol. 36(10), 1118\u20131128 (2022).","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"30172_CR57","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/6598753","volume":"2015","author":"D Gonz\u00e1lez","year":"2015","unstructured":"Gonz\u00e1lez, D., Torrens, M. & Farr\u00e9, M. Acute effects of the novel psychoactive drug 2C-B on emotions. Biomed. Res. Int. 2015(1), 643878 (2015).","journal-title":"Biomed. Res. Int."},{"issue":"8","key":"30172_CR58","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1038\/s41380-024-02506-8","volume":"29","author":"P Puigseslloses","year":"2024","unstructured":"Puigseslloses, P. et al. Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: Insights into psychoactive and thermoregulatory properties. Mol. Psychiatry 29(8), 2346\u20132358 (2024).","journal-title":"Mol. Psychiatry"},{"issue":"2\u20133","key":"30172_CR59","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejphar.2006.11.075","volume":"559","author":"F Nagai","year":"2007","unstructured":"Nagai, F., Nonaka, R. & Kamimura, K. S. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur. J. Pharmacol. 559(2\u20133), 132\u2013137 (2007).","journal-title":"Eur. J. Pharmacol."},{"key":"30172_CR60","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/SAR.S37258","volume":"21","author":"JS Meyer","year":"2013","unstructured":"Meyer, J. S. 4-methylenedioxymethamphetamine (MDMA): Current perspectives. Subst. Abuse Rehabil. 21, 83\u201399 (2013).","journal-title":"Subst. Abuse Rehabil."},{"issue":"5","key":"30172_CR61","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.3390\/biomedicines12051008","volume":"12","author":"T Mohammed","year":"2024","unstructured":"Mohammed, T. et al. Marijuana use may be associated with reduced prevalence of prostate cancer: A national survey on drug use and health study from United States of America. Biomedicines 12(5), 1008 (2024).","journal-title":"Biomedicines"},{"issue":"6","key":"30172_CR62","first-page":"1593","volume":"14","author":"EJ Siddiqui","year":"2005","unstructured":"Siddiqui, E. J., Thompson, C. S., Mikhailidis, D. P. & Mumtaz, F. H. The role of serotonin in tumour growth. Oncol. Rep. 14(6), 1593\u20131597 (2005).","journal-title":"Oncol. Rep."},{"issue":"3","key":"30172_CR63","first-page":"243","volume":"9","author":"Y Ballou","year":"2018","unstructured":"Ballou, Y. et al. 5-HT serotonin receptors modulate mitogenic signaling and impact tumor cell viability. Mol. Clin. Oncol. 9(3), 243\u2013254 (2018).","journal-title":"Mol. Clin. Oncol."},{"key":"30172_CR64","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/bs.pbr.2021.01.003","volume":"259","author":"R Colangeli","year":"2021","unstructured":"Colangeli, R., Teskey, G. C. & Di Giovanni, G. Endocannabinoid-serotonin systems interaction in health and disease. Prog. Brain Res. 259, 83\u2013134 (2021).","journal-title":"Prog. Brain Res."},{"issue":"3","key":"30172_CR65","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.neuroscience.2007.02.021","volume":"146","author":"M H\u00e4ring","year":"2007","unstructured":"H\u00e4ring, M., Marsicano, G., Lutz, B. & Monory, K. Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice. Neuroscience 146(3), 1212\u20131219 (2007).","journal-title":"Neuroscience"},{"issue":"1","key":"30172_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41416-022-01727-4","volume":"127","author":"B Hinz","year":"2022","unstructured":"Hinz, B. & Ramer, R. Cannabinoids as anticancer drugs: Current status of preclinical research. Br. J. Cancer 127(1), 1\u201313 (2022).","journal-title":"Br. J. Cancer"},{"issue":"10","key":"30172_CR67","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1111\/bph.14426","volume":"176","author":"B Hinz","year":"2019","unstructured":"Hinz, B. & Ramer, R. Anti-tumour actions of cannabinoids. Br. J. Pharmacol. 176(10), 1384\u20131394 (2019).","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"30172_CR68","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/cam4.1312","volume":"7","author":"P \u015aledzi\u0144ski","year":"2018","unstructured":"\u015aledzi\u0144ski, P., Zeyland, J., S\u0142omski, R. & Nowak, A. The current state and future perspectives of cannabinoids in cancer biology. Cancer Med. 7(3), 765\u2013775 (2018).","journal-title":"Cancer Med."},{"issue":"3982","key":"30172_CR69","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1126\/science.172.3982.431","volume":"172","author":"NI Dishotsky","year":"1971","unstructured":"Dishotsky, N. I., Loughman, W. D., Mogar, R. E. & Lipscomb, W. R. LSD and genetic damage: Is LSD chromosome damaging, carcinogenic, mutagenic, or teratogenic?. Science 172(3982), 431\u2013440 (1971).","journal-title":"Science"},{"issue":"3\u20134","key":"30172_CR70","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/0165-1110(77)90003-3","volume":"47","author":"MM Cohen","year":"1977","unstructured":"Cohen, M. M. & Shiloh, Y. Genetic toxicology of lysergic acid diethylamide (LSD-25). Mutat. Res.\/Rev. Genet. Toxicol. 47(3\u20134), 183\u2013209 (1977).","journal-title":"Mutat. Res.\/Rev. Genet. Toxicol."},{"issue":"20","key":"30172_CR71","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1056\/NEJM196711162772001","volume":"277","author":"MM Cohen","year":"1967","unstructured":"Cohen, M. M., Hirschhorn, K. & Frosch, W. A. In vivo and in vitro chromosomal damage induced by LSD-25. N. Engl. J. Med. 277(20), 1043\u20131049 (1967).","journal-title":"N. Engl. J. Med."},{"key":"30172_CR72","unstructured":"Cancer Stat Facts: Testicular Cancer. Accessed 12 December 2024; https:\/\/seer.cancer.gov\/statfacts\/html\/testis.html."},{"issue":"4","key":"30172_CR73","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1159\/000447143","volume":"9","author":"S Gupta","year":"2015","unstructured":"Gupta, S. et al. Prostate cancer: How young is too young?. Curr. Urol. 9(4), 212\u2013215 (2015).","journal-title":"Curr. Urol."},{"issue":"1","key":"30172_CR74","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41591-023-02727-4","volume":"30","author":"WR Smith","year":"2024","unstructured":"Smith, W. R., Sisti, D. A. & Appelbaum, P. S. The safety of supported psilocybin use in Oregon. Nat. Med. 30(1), 17\u201318 (2024).","journal-title":"Nat. Med."},{"issue":"6","key":"30172_CR75","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/add.14892","volume":"115","author":"D Lewer","year":"2020","unstructured":"Lewer, D. et al. Frequency of health-care utilization by adults who use illicit drugs: A systematic review and meta-analysis. Addiction 115(6), 1011\u20131023 (2020).","journal-title":"Addiction"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30172-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30172-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30172-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T14:02:34Z","timestamp":1767708154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30172-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["30172"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-30172-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"12 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"609"}}